Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 13, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 450,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,456.8861 pence per share.
- Transaction Date: April 13, 2007.
Material Changes
Following the repurchase, the Company's Treasury holdings increased to 285,642,678 shares. The total number of shares in issue (excluding Treasury shares) stands at 5,725,966,701. This figure represents the total voting rights and serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,725,966,701) for calculating ownership thresholds.
- Confirm the updated Treasury share count (285,642,678) for capital structure analysis.
- Note that this filing is a regulatory disclosure of a share buyback and does not contain operational or financial performance data.